VerImmune is an early-stage biotechnology company developing a first-in-class cancer therapy known as Anti-tumor Immune Redirection (AIR). This strategy utilizes a proprietary virus-inspired particle (ViP) platform that redirects pre-existing pathogenic or childhood vaccine immune memory towards tumors. This unique mechanism of action allows differentiation within the competitive Immuno-Oncology market. Importantly, it potentially changes the treatment paradigm for many patients who have un-treatable cancers due to limited options or resistance.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/28/22 | $2,500,000 | Seed |
Gaingels Mana Ventures NuFund Venture Group Proxima VC Seedfolio  Ulu Ventures | undisclosed |
| 09/23/24 | $4,500,000 | Pre-Series A |
Beiley Biofund Dr. John Ballantyne Gaingels Mana Ventures Proxima VC | undisclosed |
